ARTICLE INFORMATION Accepted for Publication:September 18, 2023. Published Online:October 3, 2023. doi:10.1001/jama.2023.20294 Correction: This article was corrected on October 26, 2023, to fix an error in Table 2 in which the values for change from baseline to week 52 for HbA1c and body weight were inadvertently flipped for the 15-mg and 5-mg groups Author Contributions:Dr Fernández Landó and Mr Patel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design:Fernández Landó, Patel. Acquisition, analysis, or interpretation of data:All authors. Drafting of the manuscript:Rosenstock, Tofé, Huh, Patel. Critical review of the manuscript for important intellectual content:All authors. Statistical analysis:Sears, Huh. Administrative, technical, or material support:Patel. Supervision: Rodbard, Tofé, Fernández Landó, Patel. Conflict of Interest Disclosures:Dr Rosenstock reported receiving grants from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Pfizer, and Sanofi, personal fees from Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eli Lilly and Company, Hanmi, Novo Nordisk, Oramed, Sanofi, Scholar Rock, Structure Therapeutics, Terns Pharma, and Zealand (served on scientific advisory boards and received honorarium or consulting fees) and personal fees from Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and Sanofi (received honoraria for lectures) during the conduct of the study. 